Pharmaffiliates, an end-to-end CRDMO services provider in India, will be featured at CPHI Molkem, spotlighting its comprehensive strengths—from small and large molecule development to advanced concept-to-commercial CDMO partnership expertise.

At the heart of its showcase lies Pharmaffiliates’ proven spray dried dispersions CRDMO expertise, offering scalable manufacturing solutions tailored to complex R&D workflows and commercial-stage demands.

In the biologics domain, Pharmaffiliates reinforces its position as a leading CRO by introducing its high-throughput screening CRO India services, powered by the state-of-the-art CHO DG44 platform for biologics manufacturing. Their integrated biologics process development services and biologic early development services in India deliver seamless progression from concept to preclinical readiness. The company’s monoclonal antibody analytics further ensure rigorous data quality and regulatory assurance throughout development.

Here are the detailes : https://www.pharmaffiliates.com/en/cphi-molkem
Pharmaffiliates’ presence at CPHI Molkem underlines its commitment to holistic innovation—merging robust CRDMO offerings with biologics excellence—to serve global pharmaceutical and biotech partners with precision, agility, and reliability.